Analytical Services - Inhaled Products

Access the delivery technology best suited to the needs of your development programme, including unit-dose and multi-unit dose DPIs, pMDIs and smart nebulisers, suitable for home or hospital applications.

Dry Powder Inhalers:
Options include proprietary unit- and multi-unit dose platforms, as w...

With expertise in powder and liquid formulations for small molecules and biologics, as well as a broad portfolio of proprietary device and formulation technologies, we can help you overcome the challenges of inhaled formulation development.

Dry Powder Formulation
Advanced po...

In addition to extensive development manufacturing facilities, Vectura has GMP manufacturing facilities for dry powder inhalers, pMDI and nebuliser medical devices as well as further capability to handle biological molecules. 

Our GMP manufacturing facilities and equipment are relevant-to-comme...

Our formulation, device and development services are supported by our medical, regulatory, device vigilance and pharmacovigilance teams to safeguard your programme and ensure the smoothest path to product approval.

Our in-house team can support with:

Global regulatory development strategy...

Explore the series of Learning Labs at CPHI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.

Vectura inhaled formulation, device and development services

Strategies to accelerate inhaled drug development including technology platform selection.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The future commercial success of any new inhaled medicine relies largely on the correct combination of formulation and device technology chosen for its delivery. This presentation benefits any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme?